About:
Phanes Biotech is dedicated to developing innovative treatments for neurodegenerative diseases, with a particular focus on Alzheimer's Disease (AD). They delve deep into the mechanisms of neuroinflammation and its role in the progression of neurodegenerative diseases. Their research also focuses on the aggregation of tau protein in AD and developing therapies to prevent or reverse this process. Their approach is two-pronged, tackling neurodegeneration through a combination of neuroregeneration and tau immunotherapy. Phanes Biotech’s lead neuoregeneration product, PB021, is a novel molecule that demonstrates neuroregenerative properties, offering a potential path to slow or reverse neuronal damage in AD. Their lead product for tau immunotherapy, PB43D, is a monoclonal antibody specifically designed to target and reduce tau pathology, aiming to halt the progression of AD.